Bli medlem
Bli medlem

Du är här


Medical Prognosis Institute: MPIs PRP for precision medicine to be studied with Breast Cancer experts

Hoersholm; September 14
, 2016 - Medical Prognosis Institute A/S (MPI.ST) (Denmark and Phoenix, AZ,
USA) today announced that its Personalized Response Predictor PRP(TM) is to
be studied in collaboration with Breast Cancer Experts at Danish oncology
departments. The collaboration will last until further notice. The database
for hosting the data on approximately 800 metastatic breast cancer patients
has obtained approval from the Datatilsynet (Data Protection Agency) as well
as from the Ethics Committee. The patients' tumors to be investigated are
selected from a data set of>1100 Danish Breast Cancer patients.
The aim of the study is to investigate the PRPs ability to predict whether a
patient would respond or not to anticancer treatments given during their
disease. This will be investigated by using the PRP tool to analyze the
patients' tumors genetic profile in the biopsy taken at the time of the
diagnosis - and the clinical response results documented in hospital charts.
A statistical analysis plan has been prepared ahead to demonstrate the
expected strength of the Personalized Response Predictors ability to predict
individual patients' treatment outcome.
If the PRP with statistical significance can predict treatment outcome for the
individual cancer patient the potential benefit for patients, treating
physicians and financial savings are huge.


The objective of the study is to evaluate whether the PRP in practice can
predict drug sensitivity to Fulvestrant, epirubicin and vinorelbine +
trastuzumab in patients with metastatic breast cancer by comparing the
results of the PRPs with the patient's clinical response to a particular drug

says Adjunct Professor Peter Buhl Jensen, M.D., CEO of MPI. "

Systems to match a patient and a drug are eagerly awaited


preferably each patient's tumor should be evaluated in order to single out the
drugs most likely to have an effect in the individual patients. MPI has in 29
out of 37 studies demonstrated an ability to predict response correctly in
different tumor types and drugs. The aim is to develop the PRP in
collaborations all the way to market."

Buhl Jensen further commented.

The objective of the study is to evaluate whether the PRP in practice can
predict drug sensitivity in patients with locally advanced or metastatic
breast cancer by comparing the respective PRP with the patient's clinical
response to a particular drug. The cancer drug signatures to be evaluated are
initially Fulvestrant, epirubicin and vinorelbine + trastuzumab. The primary
endpoint is time to progression and secondary endpoints are overall survival
(OS) and response. Allowance from the authorities have also been given to
include analysis of docetaxel, capecitabine, eribulin, lapatinib, tamoxifen,
gemcitabine, paclitaxel and trastuzumab which will be analyzed later.

About MPI's multiple biomarker called Drug Response Predictor - DRP(TM) and
Personalized Response Predictor - PRP(TM)
MPI's DRP(TM) and PRP(TM)are tools for developing tumor-derived genetic
signatures to predict which cancer patients will respond with a high
likelihood to a given anti-cancer product. The DRP(TM) has been tested in 37
trials, where 29 trials showed that drug-specific DRP(TM) Biomarkers could
predict which patients responded well to the treatment. The DRP(TM) platform
has amongst others been externally validated and published in collaboration
with leading statisticians at the MD Anderson Cancer Center. The DRP(TM)
method can be used to design the Clinical Development Plan, i.e. to select
which indications are relevant for a given anti-cancer drug. In addition to
this, the individual genetic patterns of patients can be analyzed as part of
a screening procedure for a clinical trial to ensure inclusion of patients
with a high likelihood of response to the drug. DRP(TM) and PRP(TM) builds on
comparison between sensitive and resistant human cancer cell lines, including
genomic information from cell lines combined with clinical tumor biology and
clinical correlates in a systems biology network. The DRP(TM) and PRP(TM) are
Big Data tools based on messenger RNA.
The DRP(TM) platform i.e. the DRP(TM) and the PRP(TM) tools can be used in all
cancer types, and is patented for more than 60 anti-cancer drugs in the US.
The DRP(TM) is used in Oncology Venture - a spinout from MPI - for drug
development. The PRP(TM) is used by MPI for Personalized Medicine.

About MPI
Medical Prognosis Institute A/S is a publicly traded international company
specialized in improving cancer patients lives by developing Personalized
Medicine using its unique DRP(TM) technology. MPI's exceptional opportunity
to personalize cancer treatment - begins with Breast Cancer moving on to
Multiple Myeloma and Prostate Cancer as the first steps. MPI's DRP(TM) tool
has shown its ability to separate patients who benefit and who do not benefit
from a specific cancer treatment. This has been shown in as many as 29 out of
37 trials, and covers more than 80 anti-cancer treatments in a wide range of
cancer indications. MPI has built a significant large database with over
1,100 screened breast cancer patients and is building up a database in
Multiple Myeloma to be followed by Prostate cancer in collaboration with
oncologists and hematologists throughout Denmark.

For further information, please contact:
CEO, Peter Buhl Jensen, Adjunct Professor, MD, PhD
Ulla Hald Buhl, IR&Communication

Telephone: +45 21 60 89 22
Telephone +45 21 70 10 49

This information is information that Medical Prognosis Institute A/S is
obliged to make public pursuant to the EU Market Abuse Regulation. The
information was submitted for publication, through the agency of the contact
person set out above, on September 14 2016.

Certified Advisor:

Sedermera Fondkommission, Norra Vallgatan 64, 211 22, Malmö, Sweden

MPI - MPIs PRP for precision medicine to be studied in clinical setup


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Medical Prognosis Institute via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.